Evodiamine and rutaecarpine can block NLRP3 inflammasome activation to ameliorate several inflammatory diseases, including gouty arthritis, colitis, and atherosclerosis (Shen et al., 2019; Ding et al., 2020; Luo et al., 2020; Cheng et al., 2023), indicating that ER, which contains these active metabolites, may be able to exert anti-gout effects by inhibiting NLRP3 inflammasome activation. Here, NLRP3 is linked to gout.